Conmed (CNMD) Liabilities and Shareholders Equity (2010 - 2026)

Conmed (CNMD) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $2.3 billion in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 1.21% year-over-year to $2.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $9.3 billion (changed 0.17% YoY) and the FY2025 annual result came in at $2.3 billion, up 0.85% from the prior year.
• Liabilities and Shareholders Equity slipped to $2.3 billion in Q2 2026, from $2.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.3 billion in Q2 2025 to a low of $1.8 billion in Q1 2022.
• A 5-year average of $2.3 billion and a median of $2.3 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 30.67% — and 2024, when it slipped 1.6%.
• Tracing CNMD's Liabilities and Shareholders Equity over 5 years: stood at $2.3 billion in 2022, then rose by 0.11% to $2.3 billion in 2023, then rose by 0.27% to $2.3 billion in 2024, then rose by 0.85% to $2.3 billion in 2025, then slipped by 1.09% to $2.3 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $2.3 billion (Q2 2026), $2.3 billion (Q1 2026), and $2.3 billion (Q4 2025), per Business Quant data.